Literature DB >> 6094807

Design, synthesis, and testing of potential antisickling agents. 5. Disubstituted benzoic acids designed for the donor site and proline salicylates designed for the acceptor site.

D J Abraham, D M Gazze, P E Kennedy, M Mokotoff.   

Abstract

This paper reports the discovery of a new class of potent antigelling agents. The new compounds, disubstituted benzoic acid derivatives, were designed by using molecular modeling experiments. These molecules contain functional groups positioned to interact with several polar amino acid residues near the Val-6 beta mutation site (donor site) in HbS. The compounds also contain a hydrophobic group designed to occupy a nonpolar ara on the surface of the protein created by several hydrophobic amino acids. The synthesis and testing of these new molecules using a standard solubility assay is reported. A structural comparison is made between one of the most active antigelling agents, compound 13, which has little effect on the oxygen affinity of Hb in solution, and bezafibrate, a known antilipidemic drug that is progelling and has a very potent effect on decreasing Hb oxygen affinity (Perutz, M. F.; Poyart, C. Lancet 1983, 2, 881-882). We also report the synthesis and testing of a series of proline-salicylate molecules designed to react covalently at the mutation acceptor area. This class of molecules did not show significant activity.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6094807     DOI: 10.1021/jm00378a005

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  6 in total

1.  Combinatorial synthesis of small-molecule libraries using 3-amino-5-hydroxybenzoic acid.

Authors:  S M Dankwardt; T M Phan; J L Krstenansky
Journal:  Mol Divers       Date:  1996-02       Impact factor: 2.943

2.  Asymmetric total synthesis of (+)- and ent-(-)-yatakemycin and duocarmycin SA: evaluation of yatakemycin key partial structures and its unnatural enantiomer.

Authors:  Mark S Tichenor; John D Trzupek; David B Kastrinsky; Futoshi Shiga; Inkyu Hwang; Dale L Boger
Journal:  J Am Chem Soc       Date:  2006-12-13       Impact factor: 15.419

Review 3.  Modulating hemoglobin allostery for treatment of sickle cell disease: current progress and intellectual property.

Authors:  Piyusha P Pagare; Aref Rastegar; Osheiza Abdulmalik; Abdelsattar M Omar; Yan Zhang; Andrew Fleischman; Martin K Safo
Journal:  Expert Opin Ther Pat       Date:  2021-11-01       Impact factor: 6.714

4.  Privileged substructures for anti-sickling activity via cheminformatic analysis.

Authors:  Chuleeporn Phanus-Umporn; Watshara Shoombuatong; Veda Prachayasittikul; Nuttapat Anuwongcharoen; Chanin Nantasenamat
Journal:  RSC Adv       Date:  2018-02-07       Impact factor: 4.036

Review 5.  Therapeutic strategies to alter the oxygen affinity of sickle hemoglobin.

Authors:  Martin K Safo; Gregory J Kato
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-21       Impact factor: 3.722

6.  Photoaffinity labelling of cyanomethaemoglobin with derivatives of tryptophan and 5-bromotryptophan.

Authors:  M Li; Z Lin; M E Johnson
Journal:  Biochem J       Date:  1995-05-15       Impact factor: 3.857

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.